Intelligent Bio Solutions Inc. logo

Intelligent Bio Solutions Inc.

INBS | NASDAQ
Chart Builder DCF Calculator
$1.75
-$0.01 (-0.57%)
Nov 2, 2026, 9:51 AM ET · Market open

Company Profile

Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Key Executives

Name Position
Harry Simeonidis President & Chief Executive Officer
Spiro Kevin Sakiris Chief Financial Officer
Anna Turkington Vice President of Marketing
Callistus Sequeira Vice President of Global Quality & Operations
Doug Heath Vice President of Global Sales
Peter Passaris Vice President of Product Development

Latest SEC Filings

Date Type Title
Sep 23, 2026 EFFECT Filing
Sep 23, 2026 424B3 Filing
Sep 15, 2026 S-3 Filing
Sep 14, 2026 D Filing
Sep 11, 2026 8-K Current Report
Sep 09, 2026 8-K Current Report
Sep 02, 2026 8-K Current Report
Sep 01, 2026 8-K Current Report
Aug 28, 2026 8-K Current Report
Aug 19, 2026 8-K Current Report
View All SEC Filings ➞
Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. logo
Country United States
IPO Date Dec 23, 2020
Industry Medical - Devices
Sector Healthcare
Employees 59
CEO Harry Simeonidis

Contact Details

142 West 57th Street New York City, New York 10036 United States

Stock Details

Ticker Symbol INBS
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001725430
CUSIP Number 36151G709
ISIN Number US36151G7097
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.